CDDO-imidazolide

CDDO-imidazolide is a synthetic oleanane triterpenoid, chemically named 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-imidazole. It acts as a potent activator of the Nrf2 pathway, conferring cytoprotective effects by increasing antioxidant and anti-inflammatory gene expression. CDDO-imidazolide exhibits protective effects in various preclinical models, including amelioration of ischemia/reperfusion-induced liver injury and hyperoxia-induced acute lung injury, mediated primarily via Nrf2 activation. It has demonstrated anti-cancer properties in models of pancreatic and triple-negative breast cancer through inhibition of inflammatory cytokines, reduction of immune cell infiltration, modulation of cancer stem cell signaling, and induction of cell cycle arrest and apoptosis. The compound has been primarily used in academic and preclinical research settings to explore potential in oncology and inflammation-related diseases[1][2][3][4][5].

Other names

1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-imidazoleCDDO-Im